Search
Print Page   |   Contact Us   |   Sign In   |   Join Today
Virginia Bio Commercialization Luncheon - March 2014
Tell a Friend About This EventTell a Friend
 

Monthly bioscience luncheon held in Richmond, VA.

3/6/2014
When: Thursday, March 6
11:30 AM - 1:30 PM
Where: Virginia Biotechnology Research Park
800 E. Leigh St.
Richmond, Virginia  23227
United States
Contact: Sherri Halloran
804-643-6360


Online registration is closed.
« Go to Upcoming Event List  

"HemoShear: a transformational story”

 

Details 

HemoShear, LLC , launched its business in 2009 with technology discovered by UVA professors Brett Blackman and Brian Warmhoff. HemoShear works in strategic partnerships with pharmaceutical and biotechnology companies to help them understand human biology, validate meaningful drug targets, and profile and select those drug candidates that are far more likely to complete human trials successfully.

 

The Company is growing rapidly in Charlottesville as it moves into greatly expanded lab and office space at the former Martha Jefferson Hospital. What few Virginians know, however, is that the Company’s breakthrough science and innovative vision are poised to transform global drug discovery and development, leading to safer and more effective therapies, reduced costs and vastly improved probability of success of new drug candidates.

Hemoshear’s science combines principles of physiological blood flow and primary human cells to accurately replicate human organ and disease biology on the bench, enabling the study of drugs at human concentrations. Their publications and proof-of-concept studies demonstrate that HemoShear’s "human-relevant” systems are far more predictive of human responses than traditional cell culture and animal testing. Hemoshear also is developing a comprehensive Human Response Database from its studies to yield insights never before available to the scientific community using cutting-edge bioinformatics and computational methods.

 

HemoShear has received funding from four separate divisions of the National Institutes of Health, including the largest ever Phase II Small Business Innovation Research award from the National Heart, Lung and Blood Institute. When HemoShear recently received an SBIR award from the National Cancer Institute - to develop a human cell-based system that would replicate the biology of lung and pancreatic tumors, Dr. Warmhoff explained, "Imagine a human tumor on the laboratory bench that responds to new therapies as if it were in the human body. That is what our science is capable of achieving.”

 

HemoShear is currently partnering with several major pharmaceutical and biotechnology companies on important drug discovery and safety programs.

 

Speakers Jim Powers, Chairman & CEO, Brian Wamhoff, Ph.D., Co-founder and Vice President of Research & Development, and Nikki Hastings, Ph.D, President of Operations

 

 

Sponsors:

 


      

 

more Events

10/1/2016 » 10/2/2016
HealthHacks

Premium Members

Membership Software Powered by YourMembership.com®  ::  Legal